title: Neutralizing activity induced by the attenuated coxsackievirus B3 Sabin3-like strain against CVB3 infection.
abstract: Coxsackievirus B3 (CVB3) causes viral myocarditis, and can ultimately result in dilated cardiomyopathy. There is no vaccine available for clinical use. In the present work, we assessed whether the Sabin3-like mutant of CVB3 could induce a protective immunity against virulent CVB3 Nancy and CVB4 E2 strains in mice by both oral and intraperitoneal (IP) routes. Serum samples, taken from mice inoculated with Sabin3-like, were assayed in vitro for their anti-CVB3 neutralizing activity. CVB3 Sabin3-like was highly attenuated in vivo and was able to induce an anti-CVB3 activity of the serum. However, at 4 days post-CVB3 challenge, significant increased titers of CVB3 neutralizing antibodies were detectable in the sera of immunized mice over the next 6 days. Non-immunized mice challenged with CVB3 Nancy had no anti-CVB3 activity in their sera until 10 days post-infection. CVB3 Nancy induced higher viral titers than did the mutant strain. There was no variation of the neutralizing activity of serum taken from mice immunized with CVB3 Sabin3-like and challenged with CVB4 E2, compared to non-immunized mice. Despite the fact that CVB3 and CVB4 are closely related viruses, virus-neutralizing activity clearly distinguish between these viruses. A variable and limited amount of pancreatic inflammation was seen in some mice 10 days after Sabin3-like inoculation by IP route, whereas there was no evidence of pancreatic damage in mice inoculated by oral route. All immunized mice were protected from myocarditis and pancreatitis at 8 days post-challenge with CVB3 or CVB4 E2. These findings strongly suggest that the mutant strain could be considered a candidate for an attenuated CVB3 vaccine.
authors: Laboratoire des Maladies Transmissibles et Substances Biologiquement Actives (LR99-ES27), Faculté de Pharmacie de Monastir, Avenue Avicenne, 5000, Biotola, Tunisia.
authors: Nadia
authors: N
authors: Jrad-Battikh
authors: Amira
authors: A
authors: Souii
authors: Leila
authors: L
authors: Oueslati
authors: Mahjoub
authors: M
authors: Aouni
authors: Didier
authors: D
authors: Hober
authors: Jawhar
authors: J
authors: Gharbi
authors: Manel
authors: M
authors: Ben M'hadheb-Gharbi
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood / Q000276:immunology*; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology*; D002648:Child; D002522:Chlorocebus aethiops; D003384:Coxsackievirus Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology*; D029822:Enterovirus B, Human / Q000235:genetics* / Q000276:immunology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000473:pathology; D051379:Mice; D009154:Mutation; D009206:Myocardium / Q000473:pathology; D009500:Neutralization Tests; D010179:Pancreas / Q000473:pathology; D014709:Vero Cells
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral